Page 54 - Read Online

Giuliani et al. Cancer Drug Resist 2021;4:740-4 https://dx.doi.org/10.20517/cdr.2021.14 Page 744

Copyright
© The Author(s) 2021.

REFERENCES
1. Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-
positive non-small cell lung cancer? Int J Mol Sci 2019;20:146. DOI PubMed PMC
2. Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of Trastuzumab and Rituximab.
Anticancer Res 2019;39:3971-3. DOI PubMed
3. Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-
small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res 2019;8:853-63. DOI PubMed
4. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can
be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-
MCBS). Ann Oncol 2015;26:1547-73. DOI PubMed
5. Giuliani J, Bonetti A. Which grade is of clinical benefit in the randomised controlled trials? Eur J Cancer 2018;104:233-5. DOI
PubMed
6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-
positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol
2011;12:735-42. DOI PubMed
7. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie
and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients
with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol 2012;13:239-46. DOI PubMed
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med
2009;361:947-57. DOI PubMed
9. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med 2010;362:2380-8. DOI PubMed
10. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-
small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol 2010;11:121-8. DOI PubMed
11. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers
with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8. DOI PubMed
12. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung
adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34. DOI PubMed
13. Wu Y, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-
small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol
2014;15:213-22. DOI PubMed
14. Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung
cancer. N Engl J Med 2018;378:113-25. DOI PubMed
15. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, Randomized, open-
label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer
in Asia (IPASS). J Clin Oncol 2011;29:2866-74. DOI PubMed
16. Ramalingam SS, Vansteenkiste J, Planchard D, et al; FLAURA Investigators. Overall survival with Osimertinib in untreated, EGFR-
mutated advanced NSCLC. N Engl J Med 2020;382:41-50. DOI PubMed
17. Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer 2020;129:41-9. DOI PubMed
18. Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998;13:664. DOI
PubMed PMC
19. Giuliani J, Bonetti A. Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check
point inhibitors. Anticancer Res 2019;39:3961-5. DOI PubMed
20. Giuliani J, Bonetti A. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice? Recenti Prog Med
2019;110:138-43. DOI PubMed
21. Giuliani J, Bonetti A. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment
based on programmed death-ligand 1 (PD-L1) level. Oral Oncol 2019;97:143-5. DOI PubMed
22. Giuliani J, Bonetti A. Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a
perspective based on pharmacologic costs. Clin Lung Cancer 2017;18:e363-5. DOI PubMed
23. Giuliani J, Bonetti A. Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma. Clin Genitourin Cancer
2018;16:e557-62. DOI PubMed
24. Giuliani J, Albanese V, Ponturo G, Bonetti A. Economic sustainability of nivolumab at flat dose for second-line treatment of
metastatic non-small cell lung cancer in real life. J Oncol Pharm Pract 2019;25:2059-60. DOI PubMed